1055027-48-9

Basic information

• Product Name: 1,2,3,4-Butanetetrol, 1-[2-(3-isoxazolyl)-1H-iMidazol-5-yl]-, (1R,2S,3R)-
• Synonyms: 1,2,3,4-Butanetetrol, 1-[2-(3-isoxazolyl)-1H-iMidazol-5-yl]-, (1R,2S,3R)-;(1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-iMidazol-4-yl)butane-1,2,3,4-tetraol;(1R,2S,3R)-1-(2-(Isoxazol-3-yl)-1H-imidazol-5-yl)butane-1,2,3,4-tetraol
• CAS NO: 1055027-48-9
• Molecular Formula: C₁₀H₁₃N₃O₅
• Molecular Weight: 255.22732
• Mol File: 1055027-48-9.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1,2,3,4-Butanetetrol, 1-[2-(3-isoxazolyl)-1H-iMidazol-5-yl]-, (1R,2S,3R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,3,4-Butanetetrol, 1-[2-(3-isoxazolyl)-1H-iMidazol-5-yl]-, (1R,2S,3R)-(1055027-48-9)
• EPA Substance Registry System: 1,2,3,4-Butanetetrol, 1-[2-(3-isoxazolyl)-1H-iMidazol-5-yl]-, (1R,2S,3R)-(1055027-48-9)

Safety Data

• Hazardous Substances Data: 1055027-48-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1,2,3,4-Butanetetrol, 1-[2-(3-isoxazolyl)-1H-imidazol-5-yl]-, (1R,2S,3R)is used as a potential pharmaceutical candidate for [application reason] due to its unique structure and stereochemistry. Further research and testing are required to explore its specific properties and therapeutic potential.
Used in Chemical Industry:
1,2,3,4-Butanetetrol, 1-[2-(3-isoxazolyl)-1H-imidazol-5-yl]-, (1R,2S,3R)is used as a chemical intermediate or building block for the synthesis of other complex organic compounds in the chemical industry. Its specific stereochemistry and functional groups may offer advantages in the development of novel materials or chemical processes.

Upstream product

• 94944-70-4 (1'R,2'S,3'R)-2-acetyl-4⁽⁵⁾-(1',2',3',4'-tetrahydroxy-1'-butyl)imidazole 

Relevant articles and documents

Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: Discovery of (E)-1-(4-((1 R,2 S,3 R)-1,2,3,4-tetrahydroxybutyl)-1 H -imidazol-2-yl)ethanone oxime (LX2931) and (1 R,2 S,3 R)-1-(2-(Isoxazol-3-yl)-1 H -imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932)

Sphingosine 1-phosphate lyase (S1PL) has been characterized as a novel target for the treatment of autoimmune disorders using genetic and pharmacological methods. Medicinal chemistry efforts targeting S1PL by direct in vivo evaluation of synthetic analogues of 2-acetyl-4(5)-(1(R),2(S),3(R),4- tetrahydroxybutyl)-imidazole (THI, 1) led to the discovery of 2 (LX2931) and 4 (LX2932). The immunological phenotypes observed in S1PL deficient mice were recapitulated by oral administration of 2 or 4. Oral dosing of 2 or 4 yielded a dose-dependent decrease in circulating lymphocyte numbers in multiple species and showed a therapeutic effect in rodent models of rheumatoid arthritis (RA). Phase I clinical trials indicated that 2, the first clinically studied inhibitor of S1PL, produced a dose-dependent and reversible reduction of circulating lymphocytes and was well tolerated at dose levels of up to 180 mg daily. Phase II evaluation of 2 in patients with active rheumatoid arthritis is currently underway.